Infliximab Preferentially Induces Clinical Remission and Mucosal Healing in Short Course Crohn’s Disease with Luminal Lesions through Balancing Abnormal Immune Response in Gut Mucosa

Table 5

Adverse effects during IFX therapy in CD patients.

Description of the events	Number of patients (%)
Any adverse events	24 (22.6%)
Any serious adverse events	0
Infusion reactions	22 (20.8%)
Fever or chills	7 (6.6%)
Primarily chest pain	0
Dyspnea	0
Myalgia	4 (3.8%)
Pruritus/rash	8 (7.5%)
Nausea/vomiting	3 (2.8%)
Anaphylaxis	0
Seizures	0
Hypotension	0
Infections	0
Hepatotoxicity	2 (1.9%)
Lupus-like syndrome	0
Psoriasiform rash	0
Deaths	0